Hexagon Bio
PrivateLast Round
Series C
Oct 23, 2026
Total Funding Raised
$194.6M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Hexagon Bio operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Series C round in October 2026.
Hexagon Bio is a biotechnology company that utilizes a synthetic biology platform and data science to discover small molecule inhibitors from fungal genomes, facilitating the identification of new medicines to enhance patient care.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hexagon Bio Comparables
Compare Hexagon Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bactobio | 82% | |
| LifeMine Therapeutics | 82% | |
| Basecamp Research | 81% |
For institutional investors. Book with your work email.
Hexagon Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 23, 2026 | ||||
| Series B | Feb 13, 2023 | ||||
| VC Round | Sep 22, 2021 | ||||
| Series A | Sep 15, 2020 | ||||
| Seed | Jun 16, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hexagon Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | VC Round, Series B, Series C, Series A |
| CPP Investments | Series C, Series B |
| SoftBank Investment Advisers | VC Round |
| bpd partners | Seed |
| SoftBank Group | VC Round |
| The Chernin Group | Series A |
| Two Sigma Ventures | VC Round, Seed, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 23, 2026
$62M round led by The Column Group.
- Dec 17, 2025
Developing natural crop protections in partnership with Corteva.
For institutional investors. Book with your work email.
Hexagon Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hexagon Bio's valuation, stock price, and market status.
Is Hexagon Bio a public or private company?
Hexagon Bio is a private company.
What is the current stock price of Hexagon Bio?
Hexagon Bio is a private company, so its shares have no public market price. Caplight tracks Hexagon Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hexagon Bio worth (valuation)?
Valuation information for Hexagon Bio is not publicly available.
Can I buy Hexagon Bio stock?
Hexagon Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hexagon Bio's last funding round?
Hexagon Bio's most recent funding round was Series C on October 23, 2026.
Who are the main investors in Hexagon Bio?
Key investors in Hexagon Bio include The Column Group, The Chernin Group, Two Sigma Ventures, Nextech Invest.
Will Hexagon Bio IPO soon?
No public IPO plans have been announced for Hexagon Bio.
How can I track Hexagon Bio secondary market activity?
Caplight tracks bids, offers, and trades in Hexagon Bio's shares on secondary markets.